Patrice Jean

Patrice P. Jean is Chair of Hughes Hubbard's Life Sciences group.  She has over a decade of experience counseling leading and startup pharmaceutical, chemical and biotechnology companies in all areas of patent law. In particular, she is adept at asserting and defending the patent rights underlying the core technologies and innovations of leading high-tech and pharmaceutical companies. She also defends her clients against claims asserted by competitors, sparing them billions of dollars in damages. Additionally, her patent prosecution practice strengthens her litigation abilities, allowing her to argue the validity of her clients' patents while challenging the validity of third-party patents. Patrice regularly calls on her technical background in biology to offer her clients an in-depth understanding of the complex science relative to each prosecution and litigation matter that she handles. This vantage point leaves her well-positioned to understand the complex science behind her clients' innovations as well as the broader market implications. Prior to law school, Patrice earned her Ph.D. in molecular biology. She conducted research in various areas of biology and biochemistry including virology, oncology, kidney disease, X-ray crystallography and narcotics addiction. Her doctoral thesis is titled "Tissue, Strain, Gender and Age Variation in the Induction of p53 Activated Transcripts in Response to Cellular Stress."

• 454 Life Sciences Corp. v. Ion Torrent Inc. et al., No. 1:15-cv-00595-JPS (D. Del.): Counsel for the patent owner in an action concerning a process called "emulsion polymerase chain reaction" for simultaneously amplifying multiple nucleic acids in a single reaction tube
• Teva Pharmaceuticals USA v. Sandoz and Teva Pharmaceuticals USA v. Mylan Pharmaceuticals et al. (S.D.N.Y.): Represented Teva in consolidated Hatch-Waxman litigations concerning proposed generic equivalents to Teva's blockbuster multiple sclerosis drug Copaxone®
• Cipla Ltd. v. Amgen (D. Del.): Represented Cipla in its patent litigation against Amgen in connection with Cipla's generic version of the prescription drug Sensipar. Achieved victory for Cipla and rejection of Amgen’s challenge
• Alda Communications Trademark Litigation: Represented Alda Communications Training Company in its defeat of an international trademark application litigation challenge. Achieved victory for Alda Communications with the trademark petition from Aldi Inc. rejected
• BASF Corp. v. SNF Holding Co. (D. Ga.): Represented SNF in the Federal Circuit’s ruling that the case had been filed in an improper venue and finding that a BASF patent was invalid and dismissed, in its entirety, a civil action for alleged patent infringement that BASF brought against SNF and several affiliates
• Wyeth v. Intervet (D. Del.): Represented Intervet in patent infringement litigation concerning patents related to porcine circovirus vaccine technology. Achieved a favorable claim construction ruling
• Intervet v. Merial Ltd. et al. (D.D.C.): Represented Intervet in patent litigation resulting in a favorable ruling including a summary judgment of noninfringement
• Pfizer v. Teva Pharmaceuticals USA et al. (D.N.J.): Represented Teva against a multibillion-dollar damages claim in a case relating to Pfizer's epilepsy drug Neurontin® (gabapentin). Achieved a favorable ruling including a summary judgment ruling
• Institut Pasteur v. Simon (E.D. Pa.): Represented Institut Pasteur and the Centre National de la Recherche Scientifique in patent litigation resulting in a favorable summary judgment ruling regarding ownership of a portfolio of 13 patents related to DNA "molecular combing" technology. The ruling confirmed that the world-renowned French research institutions are the rightful owners of the entire portfolio of patents